Avicanna Announces Pre-Clinical Data Supporting Enhanced Absorption and Patent Filing for Novel Oral Delivery Platform

Executive Summary

• Avicanna announced positive pre‑clinical pharmacokinetic results for its novel Powder Drug Delivery System (PwdRx), showing markedly higher bioavailability and faster absorption of cannabinoids versus standard MCT oil formulations.
• The company filed a provisional U.S. patent application covering the composition, methods of use, and potential therapeutic applications of the PwdRx platform.
• Management highlighted the technology’s potential to enable new pharmaceutical product opportunities for pain‑and‑inflammation indications.

Key Details

• Preclinical pharmacokinetic performance (in‑vitro model, n=16):
• 74 % higher area under the curve (AUC) vs. MCT oil formulation.
• 63 % faster time to peak plasma concentration (Tmax).
• 134 % higher peak plasma concentration (Cmax).

• All differences statistically significant (p < 0.001).

• Formulation advantages:

• Designed for highly lipophilic cannabinoids (CBD, CBG, THC, CBN) with poor water solubility.
• Enables solid‑oral and powder formats – tablets, capsules, sachets, pouches.
• Provides long‑term stability and scalable manufacturing.

• Allows tunable drug‑release profiles for differentiated patient therapies.

• Provisional patent filing (USPTO):

• Covers composition of the PwdRx platform, methods of use, and utility in pain and inflammation treatments.

• Target indications include rheumatoid arthritis, osteoarthritis, neuropathic pain, fibromyalgia, migraine, and multiple sclerosis.

• Management commentary:

• Dr. Karolina Urban (EVP, Medical & Scientific Affairs) noted the platform “improves dispersion, solubility and consistency of uptake,” offering greater flexibility for health‑care providers.
• CEO Aras Azadian stated the technology “will unlock potential new and different pharmaceutical and commercial product opportunities” and strengthens Avicanna’s IP portfolio.

Notable Quotes

• Dr. Karolina Urban: “By improving dispersion, solubility and consistency of uptake, the PwdRx platform has the potential to enable health care providers greater flexibility to tailor potential treatment options for patients managing conditions associated with pain and inflammation.”
• Aras Azadian (CEO): “We believe this novel technology will unlock potential new and different pharmaceutical and commercial product opportunities and further demonstrates Avicanna’s leadership in advancing innovation in the science and technology of cannabinoids.”